Search clinical trials for: Lulizumab

Total 107 results

Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Genentech, Inc.

Completed

A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria

Urticaria

Germany, Canada
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Taiwan, Malaysia, Thailand, Romania, India, Mexico, Ukraine
Alexion

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

Canada, United Kingdom, France, Germany, Netherlands, Sweden, Italy
Alexion Pharmaceuticals

Completed

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Hemoglobinuria, Paroxysmal

United States, Australia, Belgium, Canada, Germany, Italy, United Kingdom, France, Ireland, Netherlands, Sweden, Switzerland
Nantes University Hospital

Completed

Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS (STOPECU)

Atypical Hemolytic Uremic Syndrome

France
Alexion

Approved for marketing

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol (EMBRACE)

Hemoglobinuria, Paroxysmal

United States
Alexion

Completed

Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma

Allergic Asthma

Canada
Alexion Pharmaceuticals

Terminated

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Canada, United Kingdom
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) (STEC-HUS)

Shiga-like Toxin-producing Escherichia Coli

Germany
Alexion Pharmaceuticals

Completed

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, Korea, Republic of, United States, Croatia, Australia, Canada, Malaysia, Japan, Italy, Turkey, Spain, Taiwan, Argentina, Colombia, Czechia, Denmark, Germany, Russian Federation, Thailand, United Kingdom
Alexion Pharmaceuticals

No longer available

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

COVID-19 | Pneumonia, Viral | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

United States, France
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) (aHUS)

Atypical Hemolytic Uremic Syndrome

Canada, United Kingdom, France, Germany, Sweden, Netherlands, Italy
Alexion Pharmaceuticals

Completed

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Hemoglobinuria, Paroxysmal

United States, United Kingdom, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland
Marmara University
National Institute of Allergy and Infectious Diseases (NIAID)

Unknown

Transcriptome and Metabolic Analyses of CHAPLE Disease (CHAPLEOMIC)

Protein-Losing Enteropathies | CD55 - Cluster of Differentiation Antigen 55 Deficiency | Primary Intestinal Lymphangiectasis | Complement Regulatory Factor Defect

Turkey
Alexion Pharmaceuticals

Completed

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Hemoglobinuria, Nocturnal

United States, Australia, Belgium, Canada, Germany, Italy, Spain, Sweden, United Kingdom, France, Ireland, Netherlands
AO GENERIUM

Completed

Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH

Paroxysmal Nocturnal Hemoglobinuria | Marchiafava-Micheli Syndrome | Paroxysmal Hemoglobinuria

Russian Federation
Biocad

Completed

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

Healthy Subjects

Russian Federation
Russian Academy of Medical Sciences

Completed

Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

End-Stage Renal Disease | Kidney Failure | Graft Reperfusion Injury

Russian Federation
Weill Medical College of Cornell University

Completed

Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants

Thrombotic Microangiopathy | Disorder Related to Bone Marrow Transplantation

United States
University Hospital, Tours
Hospices Civils de Lyon; University Hospital, Strasbourg, France; University... and other collaborators

Active, not recruiting

Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) (EspacECU)

Hemolytic-Uremic Syndrome, Atypical

France
University Hospital, Rouen

Not yet recruiting

Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies (GEMECULI)

Thrombotic Microangiopathies

France
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Lupus

Taiwan, United States, Canada, Italy, Mexico, South Africa, Korea, Republic of, Japan, France, Spain, Argentina, Hungary, Colombia, Peru, Poland, Puerto Rico, Romania, Brazil, Chile, Germany, Lebanon, Netherlands, Russian Federation
Jonsson Comprehensive Cancer Center

Completed

Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

Leukemia

United States
Radboud University Medical Center

Completed

The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PREPARE)

Paroxysmal Nocturnal Hemoglobinuria | Eculizumab | PK-PD

Netherlands
AO GENERIUM

Completed

A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation) (NAP)

Paroxysmal Nocturnal Hemoglobinuria

Russian Federation
Sanjay Kulkarni
Alexion Pharmaceuticals

Completed

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

Kidney; Complications, Allograft

United States
Columbia University
Alexion Pharmaceuticals

Completed

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Dense Deposit Disease | Membranoproliferative Glomerulonephritis

United States
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Withdrawn

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

United States
Johns Hopkins University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

The Use of Eculizumab in HELLP Syndrome

Morbidity;Newborn | Preeclampsia Severe | Complement Abnormality | HELLP Syndrome (HELLP), Third Trimester | Maternal Injury

United States
Cedars-Sinai Medical Center
Alexion Pharmaceuticals

Completed

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation (DUET)

Cardiac Allograft Vasculopathy | Antibody-mediated Rejection | Left Ventricular Dysfunction | Hyperacute Rejection of Cardiac Transplant | Heart Graft Dysfunction

United States
Johns Hopkins University

Completed

Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome

End Stage Renal Disease | Antiphospholipid Antibody Syndrome

United States
Alexion Pharmaceuticals

Completed

Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Stage V Chronic Kidney Disease

Australia, France, Italy, Spain, United Kingdom, Sweden
Mario Negri Institute for Pharmacological Research
Alexion Pharma Italy s.r.l.

Completed

Eculizumab in Primary MPGN (EAGLE)

Membranoproliferative Glomerulonephritis

Italy
Alexion Pharmaceuticals, Inc.

Completed

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Myasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile Form

United States, Japan, Netherlands
Assistance Publique - Hôpitaux de Paris

Unknown

CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort (CORIMUNO19-ECU)

SARS-CoV-2 | COVID19

France
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects

Healthy

Germany
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Hemoglobinuria, Nocturnal

United States
Alexion Pharmaceuticals

Completed

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

Japan
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion Pharmaceuticals, Inc.
AstraZeneca

Recruiting

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China (Soliris)

Atypical Hemolytic Uremic

China
Hudson Medical

Available

Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19)

Coronavirus
Alexion

Completed

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Atypical Hemolytic-Uremic Syndrome

United Kingdom, United States, France, Italy, Germany, Spain, Belgium
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion Pharmaceuticals

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Atypical Hemolytic-Uremic Syndrome

United Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

Paroxysmal Nocturnal Hemoglobinuria

United States, Korea, Republic of, Spain, Germany, Estonia, Japan, Colombia, Saudi Arabia, Turkey, Brazil, France, Greece, Poland, Taiwan, Netherlands, Italy, Australia, Sweden, Singapore, Portugal, Hungary, Belgium, Canada, Czechia, Hong... and more
Alexion Pharmaceuticals, Inc.
AstraZeneca

Active, not recruiting

Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China (Soliris)

Paroxysmal Nocturnal Hemoglobinuria

China
AO GENERIUM

Completed

Observational Study of Elizaria® in aHUS Patients

Atypical Hemolytic Uremic Syndrome | aHUS

Russian Federation
Alexion Pharmaceuticals

Terminated

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment (EVIDENCE)

Atypical Hemolytic Uremic Syndrome

United States, Australia, Germany, United Kingdom
Alexion Pharmaceuticals
CMIC Co, Ltd. Japan

Completed

E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Paroxysmal Nocturnal Hemoglobinuria

Search clinical trials for: Lulizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations